Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 30 (1) , 88-96
- https://doi.org/10.1016/j.cct.2008.09.003
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Prevalence of Elevated Alanine Aminotransferase Among US Adolescents and Associated Factors: NHANES 1999–2004Gastroenterology, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneHepatology, 2003
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand RosiglitazoneHepatology, 2003
- Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot studyThe Journal of Pediatrics, 2000
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998